CardiOS' unique formulation of bioactive ingredients may: Facilitate integration of calcium into bone. Assist in osteoporosis. Help reduce bone loss in post-menopausal women. Support cardiovascular health, endothelial function. Activate liver detoxification enzymes. Help improve working memory. Relieve insomnia and enhance sleep quality. Help regulate redox balance. CardiOS is a unique formulation designed to address key functions in cardiovascular health, bone health, stress management and cognitive decline via the selection of complementary bioactives at doses demonstrated to significantly impact the physiological systems they are targeting. CardiOS addresses major factors associated with age-related physiological decline and as such, may significantly benefit those approaching mid-life and beyond. Clinical Data shows that compounds in CardiOS may: Help remove unwanted calcium deposits from blood vessel walls. Assist in depositing calcium into bone. Help reduce the morning cortisol levels which promote a degree of heightened anxiety. CardiOS is a unique formulation which simultaneously targets cardiovascular and bone health, both of which significantly deteriorate during the ageing process. As such, CardiOS may favourably contribute to reducing these major elements of the chronic disease spectrum. The multi-functional applications for CardiOS extend well past its ability to reduce bone loss and arterial calcification; CardiOS may also provide benefit in anxiety states and where elevated cortisol facilitates chronic disease. One of its ingredients, Sensoril assists in re-ducing inflammation as well as helping to restore the normal function to the lining of blood vessels. Taking the recommended two capsules of CardiOS daily provides 4 key ingredients: MenaQ7 ™ 180 micrograms of menaquinone-7 (MenaQ7™) which has been shown in clinical trials to facilitate integration of calcium into bone and to remove unwanted calcium from arteries Sensoril™ 30 mg of withanolides (std) from 625 mg of leaves and 625 mg of roots of Withania somnifera EnduraCell® 200 mg sulforaphane-yielding 100% whole dried broccoli sprouts, activating cell defences. Vitamin D3 1000 IU of Vitamin D3 to assist in the synthesis of the bone-forming protein osteocalcin. WHO CAN BENEFIT FROM CardiOS? The following signs of declining physiology are especially common to both ANDROPAUSAL MEN and MENOPAUSAL & POST-MENOPAUSAL WOMEN: Cardiovascular disease, incl. endothelial dysfunction with calcification of smooth muscle and ar-terial plaque. Osteoporotic and osteopenic bone loss. Cognitive impairment, affecting working memory and psychomotor performance Anxiety, depression, insomnia and related conditions. Declining antioxidant/ detoxification enzyme activity and impairment in other endogenous de-fences. Ingredients Ingredient Per 1 cap Colecalciferol (Vitamin D3) 12.5 mg equiv. Vitamin D3 500 IU Menaquinone 7 (Vitamin K2) (MenaQ7®) 90 mcg Brassica oleracea var. italica (Broccoli) sprout extract dry (EnduraCell®) 100 mg equiv. sprout dry 100 mg Withania somnifera (Withania/Ashwagandha) root extract (Sensoril®) 125 mg equiv. root dry 625 mg Withania somnifera (Withania/Ashwagandha) leaf extract (Sensoril®) 125 mg equiv. leaf dry equiv. Withanolides 625 mg 30 mg Note: Cell-Logic EnduraCell® is hydroganically grown in a carefully controlled environment to maximise bioactivity. Our hydroganic growing process does not use any herbicides, pesticides or other harmful chemicals. CardiOS is GMO free. Directions for Use Adults: Take 1 vegetable capsule twice daily or as directed by a health care practitioner. Children: Not recommended for children. Store below 30°C away from light and moisture.May be refrigerated. Warnings This product contains Vitamin K2 and as with all Vitamin K supplements, should not be taken in combination with anti-coagulant therapy such as warfarin. Vitamin supplements should not replace a balanced diet. Very occasionally, gastro-intestinal adverse effects have been reported, and include nausea, gastro-abdominal discomfort and diarrhoea. Limited data available seem to indicate that such effects are limited to certain pre-existing gastro-intestinal conditions, in particular, those with dysbiosis. Howeer, it has been observed that for those affected, the dose can be managed in a manner whereby the symptoms disappear and may not recur even after the consumption of larger doses. Resources TGA Listed product with Aust L 260065.
